基本信息
文件名称：antitumor activity of 788 in nsclc with egfr exon 20中抗肿瘤活性与外显子.pptx
文件大小：4.94 MB
总页数：16 页
更新时间：2025-05-21
总字数：约1.69千字
文档摘要

AntitumoractivityofTAK-788inNSCLCwithEGFRexon20insertionsPresentedByPasiJanneat2019ASCOAnnualMeeting

EGFRExon20InsertionsinNSCLCPresentedByPasiJanneat2019ASCOAnnualMeeting

TAK-788HasPotentandSelectivePreclinicalInhibitoryActivityAgainstEGFRExon20InsertionsPresentedByPasiJanneat2019ASCOAnnualMeeting

TAK-788Dose-EscalationSchemaPresentedByPasiJanneat2019ASCOAnnualMeeting

StudyDesign:Phase1/2TrialofOralTAK-788(NCbr/br/PresentedByPasiJanneat2019ASCOAnnualMeeting

EfficacyandSafetyofTAK-788:CurrentAnalysisPresentedByPasiJanneat2019ASCOAnnualMeeting

DemographicsandBaselineCharacteristicsforPatientsTreatedWithTAK-788PresentedByPasiJanneat2019ASCOAnnualMeeting

StudyStatusofPatientswithEGFRExon20InsertionsTreatedWithTAK-788at160mgqdPresentedByPasiJanneat2019ASCOAnnualMeeting

TAK-788AntitumorActivityinPatientsWithEGFRExon20InsertionsPresentedByPasiJanneat2019ASCOAnnualMeeting

TAK-788AntitumorActivityinPatientsWithEGFRExon20InsertionsPresentedByPasiJanneat2019ASCOAnnualMeeting

OverallResponsetoTAK-788andTimeonTreatment,byPatientPresentedByPasiJanneat2019ASCOAnnualMeeting

SafetySummaryinPatientsTreatedWithTAK-788PresentedByPasiJanneat2019ASCOAnnualMeeting

Treatment-RelatedAEsinPatientsTreatedWithTAK-788PresentedByPasiJanneat2019ASCOAnnualMeeting

SummaryPresentedByPasiJanneat2019ASCOAnnualMeeting

FutureDirectionsforTAK-788PresentedByPasiJanneat2019ASCOAnnualMeeting

AcknowledgmentsPresentedByPasiJanneat2019ASCOAnnualMeeting